Avivagen (Avivagen) Cash-to-Debt : 0.00 (As of Jul. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Avivagen Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Avivagen's cash to debt ratio for the quarter that ended in Jul. 2023 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Avivagen couldn't pay off its debt using the cash in hand for the quarter that ended in Jul. 2023.

The historical rank and industry rank for Avivagen's Cash-to-Debt or its related term are showing as below:

During the past 13 years, Avivagen's highest Cash to Debt Ratio was No Debt. The lowest was -7.35. And the median was 0.69.

VIVXF's Cash-to-Debt is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.945
* Ranked among companies with meaningful Cash-to-Debt only.

Avivagen Cash-to-Debt Historical Data

The historical data trend for Avivagen's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Avivagen Cash-to-Debt Chart

Avivagen Annual Data

Trend

Oct13

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Cash-to-Debt

Get a 7-Day Free Trial

0.98

0.24

0.11

0.21

0.05

Avivagen Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Cash-to-Debt	Get a 7-Day Free Trial															0.09	0.05	-	-	-

Competitive Comparison of Avivagen's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Avivagen's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avivagen's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avivagen's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Avivagen's Cash-to-Debt falls into.

Avivagen Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Avivagen's Cash to Debt Ratio for the fiscal year that ended in Oct. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.212	/	(0.61	+	3.836)
	=	0.05

Avivagen's Cash to Debt Ratio for the quarter that ended in Jul. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.013	/	(4.646	+	0.834)
	=	0.00

Avivagen (OTCPK:VIVXF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Avivagen Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Avivagen's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Avivagen (Avivagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avivagen Inc (OTCPK:VIVXF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

VIV:Canada

Address

100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6

Website

https://www.avivagen.com

Avivagen Inc is a Canadian-based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal's health defenses. The company's products are based on OxC-beta Technology. Its geographical segments include the Philippines, which is the key revenue driver; Mexico; Thailand; United States; Malaysia; Taiwan; Brazil; and others.